Table 2.
Plasma Concentrations of BMS-986231 and its Principal (Inactive) Metabolite, BMT-284730, in Groups A and B2 Animals at Specified Time Intervals After the Start of BMS-986231 Infusion
| BMS-986231 Infusion (μg/kg/min) | Plasma Concentration (ng/ml) |
||||
|---|---|---|---|---|---|
| +2 h | +3 h | +4 h | Washout (+1 h Post-Infusion) | ||
| Group A: Coronary microembolization-induced heart failure | |||||
| 0.7 | BMS-986231 | 59 ± 12 | N/A | 137 ± 20 | 42 ± 7 |
| BMT-284730 | 21 ± 3 | N/A | 48 ± 6 | 47 ± 7 | |
| 2 | BMS-986231 | 102 ± 15 | N/A | 207 ± 46 | 46 ± 8 |
| BMT-284730 | 58 ± 4 | N/A | 127 ± 11 | 119 ± 11 | |
| 7 | BMS-986231 | 489 ± 53 | N/A | 490 ± 41 | 101 ± 12 |
| BMT-284730 | 233 ± 15 | N/A | 466 ± 34 | 407 ± 28 | |
| Group B2: Pacing-induced cardiomyopathy | |||||
| 25 | BMS-986231 | N/A | 806 ± 80 | — | — |
| BMT-284730 | N/A | 1,200 ± 118 | — | — | |
| 50 | BMS-986231 | N/A | 1,272 ± 72 | — | — |
| BMT-284730 | N/A | 2,390 ± 314 | — | — | |
| 75 | BMS-986231 | N/A | 1,790 ± 159 | — | — |
| BMT-284730 | N/A | 3,868 ± 297 | — | — | |
NA = not available; — not applicable.
Values are mean ± SD. N = 6 plasma samples per dose infusion.